disease

ALS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

17396Connections

30Hypotheses

30Analyses

50Outgoing

50Incoming

0Experiments

20Debates

Summary

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disorder affecting upper and lower motor neurons. Approximately 10% of cases are familial, with mutations in genes including SOD1, C9orf72, TARDBP (TDP-43), and FUS. ALS pathology involves protein aggregation, RNA processing defects, mitochondrial dysfunction, and neuroinflammation.

View on Wiki →

No AI portrait yet

Disease Info

Phase	Phase 2
Status	Completed
Drug	Amiloride (amiloride hydrochloride)
Dosage	10-20 mg daily
Patient Population	Adults with definite or probable ALS
Duration	12 months
ClinicalTrials.gov Identifier	NCT00879710
ASIC Inhibition	Blocks acid-sensing ion channels[@waldmann2019]
Sodium Channels	Modulates voltage-gated sodium channels
Calcium Channels	Affects calcium channel function
pH Sensitivity	Reduces acid-induced neuronal damage
Glutamate Reduction	May reduce excitotoxic damage
Associated Genes	5-HT1AR, AADC, ABCA1, ABCA7, ABCB1, ABCD3, ABCG1, ACE
Therapeutic Agents	antioxidant interventions, Antioxidants, Anti-oxidant Therapies, Antisense Oligonucleotides, Edavarone, Estradiol
SciDEX Hypotheses	28 hypotheses
KG Connections	8143 knowledge graph edges
Databases	OMIM Orphanet ClinicalTrials PubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

amiloride-als

clinical_trial · 3477 words

→

Validated Hypothesis: Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD

hypothesis · 5607 words

→

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        ALS["ALS"] -->|"associated with"| FTD["FTD"]
        ALS["ALS"] -->|"associated with"| NEURON["NEURON"]
        ALS["ALS"] -->|"associated with"| TAU["TAU"]
        ALS["ALS"] -->|"associated with"| MICROGLIA["MICROGLIA"]
        ALS["ALS"] -->|"associated with"| Als["Als"]
        ALS["ALS"] -->|"associated with"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
        ALS["ALS"] -->|"associated with"| Autophagy["Autophagy"]
        C9ORF72["C9ORF72"] -->|"causes"| ALS["ALS"]
        SOD1["SOD1"] -->|"causes"| ALS["ALS"]
        OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"associated with"| ALS["ALS"]
        AXONAL_TRANSPORT_DEFECTS["AXONAL TRANSPORT DEFECTS"] -->|"associated with"| ALS["ALS"]
        AMYOTROPHIC_LATERAL_SCLEROSIS["AMYOTROPHIC LATERAL SCLEROSIS"] -->|"associated with"| ALS["ALS"]
    end
    subgraph Signaling["Signaling"]
        ALS["ALS"] -->|"activates"| Neurodegeneration["Neurodegeneration"]
        ALS["ALS"] -->|"activates"| Als_1["Als"]
    end
    subgraph Therapeutic["Therapeutic"]
        NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"] -->|"therapeutic target"| ALS["ALS"]
    end
    style ALS fill:#ef5350,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style FTD fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEURON fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style TAU fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Amyotrophic_Lateral_Sclerosis fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_1 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style C9ORF72 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style SOD1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style OXIDATIVE_STRESS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AXONAL_TRANSPORT_DEFECTS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AMYOTROPHIC_LATERAL_SCLEROSIS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEURODEGENERATIVE_DISEASES fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (4767)

Target	Relation	Type	Str
Synaptic Plasticity	regulates	pathway	1.00
Er Stress	activates	pathway	1.00
Mtor	therapeutic_target	pathway	1.00
Immune Response	regulates	pathway	1.00
Autophagy	regulates	pathway	1.00
Apoptosis	activates	pathway	1.00
Cholesterol	activates	pathway	1.00
Phagocytosis	regulates	pathway	1.00
Mapk	therapeutic_target	pathway	1.00
Lipid Metabolism	therapeutic_target	pathway	1.00
Mitophagy	regulates	pathway	1.00
Ferroptosis	regulates	pathway	1.00
Autophagy	inhibits	pathway	1.00
Epigenetic	regulates	pathway	1.00
Mitochondrial Function	activates	pathway	1.00
Mitochondrial Function	regulates	pathway	1.00
Longevity	associated_with	disease	1.00
Blood-Brain Barrier	therapeutic_target	pathway	1.00
Lipid Metabolism	regulates	pathway	1.00
Blood-Brain Barrier	inhibits	pathway	1.00
Angiogenesis	therapeutic_target	pathway	1.00
Blood-Brain Barrier	activates	pathway	1.00
Complement	therapeutic_target	pathway	1.00
Ferroptosis	associated_with	pathway	1.00
Proteasome	activates	pathway	1.00
Ferroptosis	inhibits	pathway	1.00
Innate Immunity	regulates	pathway	1.00
Epigenetic	activates	pathway	1.00
Wnt	therapeutic_target	pathway	1.00
Glycolysis	activates	pathway	1.00
Autophagy	interacts_with	pathway	1.00
Epigenetic	therapeutic_target	pathway	1.00
Ubiquitin-Proteasome	activates	pathway	1.00
Oxidative Stress	activates	pathway	1.00
Mtor	inhibits	pathway	1.00
Oxidative Stress	regulates	pathway	1.00
Mtor	activates	pathway	1.00
Autophagy	therapeutic_target	pathway	1.00
Complement	activates	pathway	1.00
Phagocytosis	activates	pathway	1.00
Nf-Κb	activates	pathway	1.00
Innate Immunity	activates	pathway	1.00
Apoptosis	therapeutic_target	pathway	1.00
Lipid Metabolism	activates	pathway	1.00
Angiogenesis	activates	pathway	1.00
Mtor	interacts_with	pathway	1.00
Autophagy	activates	pathway	1.00
Wnt	activates	pathway	1.00
Immune Response	activates	pathway	1.00
Complement	regulates	pathway	1.00

Incoming (12629)

Source	Relation	Type	Str
entities-hepcidin	associated_with	wiki	0.00
entities-ros	associated_with	wiki	0.00
entities-atp7b-gene	associated_with	wiki	0.00
entities-reactive-oxygen-species	associated_with	wiki	0.00
entities-astrocytes	associated_with	wiki	0.00
entities-glp1-receptor	associated_with	wiki	0.00
entities-histone-methylation	associated_with	wiki	0.00
entities-microtubules	associated_with	wiki	0.00
entities-heat-shock-proteins	associated_with	wiki	0.00
OVERVIEW	therapeutic_target	gene	1.00
TREM2	activates	gene	1.00
TNF	activates	gene	1.00
GFAP	biomarker_for	gene	1.00
SQSTM1	activates	gene	1.00
MTOR	regulates	gene	1.00
NFL	biomarker_for	gene	1.00
SLC7A11	activates	gene	1.00
PTEN	activates	gene	1.00
LC3	activates	gene	1.00
PARKIN	regulates	gene	1.00
OVERVIEW	regulates	gene	1.00
GPX4	activates	gene	1.00
APOE	activates	gene	1.00
BAX	inhibits	gene	1.00
JUN	therapeutic_target	gene	1.00
JUN	activates	gene	1.00
OPTN	interacts_with	gene	1.00
MTOR	therapeutic_target	gene	1.00
SOD1	causes	gene	1.00
GAPDH	activates	gene	1.00
SOD1	therapeutic_target	gene	1.00
BDNF	activates	gene	1.00
STING	activates	gene	1.00
APOE	inhibits	gene	1.00
SOD1	associated_with	gene	1.00
SIRT1	regulates	gene	1.00
LC3	interacts_with	gene	1.00
MTOR	inhibits	gene	1.00
MYC	activates	gene	1.00
BECN1	activates	gene	1.00
TNF	expressed_in	gene	1.00
MTOR	activates	gene	1.00
APOE	regulates	gene	1.00
TBK1	activates	gene	1.00
GPX4	inhibits	gene	1.00
MAP1LC3B	activates	gene	1.00
C9ORF72	causes	gene	1.00
PIEZO1	activates	gene	1.00
APOE	therapeutic_target	gene	1.00
MTOR	interacts_with	gene	1.00

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
eIF2α Phosphorylation Imbalance Creates Integrated Stress Re	0.896	als	-
TBK1 Loss Locks Microglia in an Aged/Senescent Transcription	0.878	als	What are the mechanisms by which microgl
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
SFPQ Paralog Displacement Triggers Cryptic Polyadenylation a	0.864	als	-
hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport F	0.851	als	-

ATM Kinase Hyperactivation Triggers DNA Damage Response Over	0.837	als	-
TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE	0.828	multi	Cross-disease neurodegeneration mechanis
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43	0.824	neurodegeneration	What are the mechanisms by which gut mic
GLE1-Mediated mRNA Export Defect Creates Translation-Compete	0.823	als	-
STING Antagonists as ALS Therapeutics: Drug Repurposing	0.821	neuroinflammation	How does chronic cGAS/STING activation d
C9ORF72 autophagy-lysosome collapse across ALS and FTD	0.816	multi	Cross-disease neurodegeneration mechanis
TIA1 Low-Complexity Domain Oxidation Drives Aberrant Stress	0.810	als	-
TREM2-APOE microglial state switching across AD, ALS, and PD	0.804	multi	Cross-disease neurodegeneration mechanis
MATR3 Nuclear Body Disruption Impairs RNA Processing Hubs an	0.801	als	-
PINK1/Parkin mitophagy failure across PD, AD, and ALS	0.796	multi	Cross-disease neurodegeneration mechanis
HDAC6 Inhibition for Charcot-Marie-Tooth Disease and ALS	0.793	neurodegeneration	Test
Therapeutic Window Exists Because Amplified Signals (Not Bas	0.780	neurodegeneration	Do pathogenic LRRK2 mutations amplify vo
Stress-granule RNA-binding protein phase transition across A	0.780	multi	Cross-disease neurodegeneration mechanis
TBK1-OPTN-p62 selective autophagy failure across ALS, FTD, a	0.776	multi	Cross-disease neurodegeneration mechanis
ASO-mediated reduction of toxic C9orf72 dipeptide repeat pro	0.760	neurodegeneration	Test
STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Functio	0.760	als	Causal Sequence of TDP-43 Nuclear Cleara
GRN/progranulin lysosomal insufficiency across FTD, ALS-spec	0.756	multi	Cross-disease neurodegeneration mechanis
GPX4 reserve failure gates selective ALS motor-neuron ferrop	0.745	neurodegeneration	Ferroptosis in ALS motor neuron vulnerab
C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD	0.720	neurodegeneration	Test Hypothesis Fixtures
SASP-Secreted MMP-9 from Senescent Microglia Generates Patho	0.718	als	What are the mechanisms by which microgl
EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia	0.714	als	What are the mechanisms by which microgl
Liquid-to-Solid Transition Pathology Reveals Granule Weak Po	0.712	neurodegeneration	What determines the specificity of RNA-p
ACSL4 lipid remodeling creates ferroptosis-prone ALS membran	0.710	neurodegeneration	Ferroptosis in ALS motor neuron vulnerab
TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio	0.000	als	What are the mechanisms by which microgl
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote	0.000	als	-

Mentioning Analyses (30)

Scientific analyses that reference this entity

Cross-disease neurodegeneration mechanism synthesis

neurodegeneration | 2026-04-28 | 17 hypotheses Top: 0.828

Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Mo

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.760

Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular De

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

Oxidative Stress Upstream of TDP-43 Mislocalization in ALS Motor Neurons

neurodegeneration | 2026-04-27 | 0 hypotheses

CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.682

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (18)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiqui [PMID:30966861]	["Han X", "Sun S", "Sun Y", "Song Q", "Z	Autophagy	2020	1
Activation of stimulator of interferon genes (STING) and inhibition of vascular [PMID:41380972]	Wang Y, Hou Y, Han J, Zhang Z, Cheng Y e	J Biol Chem	2026	0
cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeut [PMID:41481960]	Fazal F, Dar NJ, Ahamad S, Khan S, Bano	Mol Aspects Med	2026	0
Opportunities and challenges of targeting cGAS-STING in cancer. [PMID:41486397]	Lu C, Wang W, Fu YX	Nat Rev Cancer	2026	0
cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifyi [PMID:41500413]	Solomon J, Mandal S, Aran KR	Gene	2026	0
STING-NF-κB signaling builds an influenza spillover barrier. [PMID:41747053]	Ye R, Wang S, Hu Y, Pan Y, Zheng W et al	Science	2026	0
The cGAS-STING signaling pathway: A central regulator and novel therapeutic targ [PMID:41765111]	Jiang H, Ji Y, Shang T, Qi L, Li Z et al	Biochem Pharmacol	2026	0
cGAS-STING and PANoptosis: Interplay, Underlying Mechanisms, and Therapeutic Tar [PMID:42016387]	Wang Y, Chen J, Feng W, Li N, Zhang X et	Drug Des Devel Ther	2026	0
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438]	Hegdekar N, Sarkar C, Bustos S, Ritzel R	Autophagy	2023	0
Inflammasome assembly in neurodegenerative diseases. [PMID:37633753]	Singh J, Habean ML, Panicker N	Trends in neurosciences	2023	0
NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pat [PMID:34877938]	Li S, Sun Y, Song M, Song Y, Fang Y, Zha	JCI insight	2021	0
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-de [PMID:30643298]	Melamed Ze'ev; López-Erauskin Jone;	Nature neuroscience	2019	0
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-de [PMID:30643298]	Melamed Z, López-Erauskin J, Baughn MW,	Nature neuroscience	2019	0
Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential thera [PMID:30127392]	Fujimori K, Ishikawa M, Otomo A, Atsuta	Nature medicine	2018	0
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodeg [PMID:30381407]	Gordon R, Albornoz EA, Christie DC, Lang	Science translational medicine	2018	0
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-lin [PMID:21944779]	Unknown	Neuron	2011	0
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. [PMID:17469117]	Unknown	Annals of neurology	2007	0
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic latera [PMID:17023659]	Unknown	Science (New York, N.Y.)	2006	0

Debates (20)

Multi-agent debates referencing this entity

Structured research brief: Stathmin-2 Splice Switching to Prevent Axonal Degener

archived · Rounds: 2 · Score: 0.73 · 2026-04-28

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

closed · Rounds: 4 · Score: 0.72 · 2026-04-28

Test question for preregistration

closed · Rounds: 4 · Score: 0.77 · 2026-04-28

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

closed · Rounds: 4 · Score: 0.64 · 2026-04-28

What are the relative contributions of cell-autonomous motor neuron mechanisms v

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

How does the CCL2-CCR2 chemokine axis at the neuromuscular junction drive select

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

What is the precise causal sequence of molecular events linking TDP-43 nuclear c

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

Can targeting oxidative stress pathways (NRF2, SOD1, mitochondrial ROS) upstream

closed · Rounds: 6 · Score: 0.62 · 2026-04-27

Debate: TREM2 Microglial Activation Rescues Amyloid Clearance in AD

closed · Rounds: 4 · Score: 0.75 · 2026-04-27

Debate: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fu

closed · Rounds: 4 · Score: 0.33 · 2026-04-27

Related Research

Hypotheses and analyses mentioning ALS in their description or question text

ALS

Understanding Entity Pages

Summary

Wiki Pages (21)

amiloride-als

Validated Hypothesis: Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD

ALS Failed Approaches Analysis

Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Lateral Sclerosis

Epigenetic Dysregulation Comparison -- AD/PD/ALS/FTD/HD

Pre-symptomatic Conversion Windows in ALS Genetic Risk Carriers

Lipid Metabolism Dysfunction Comparison — AD/PD/ALS/FTD/HD

Autophagy-Lysosomal Impairment Comparison — AD/PD/ALS/FTD/HD

Neuroinflammation Across AD, PD, ALS, FTD, and HD

ALS-FTD Spectrum

Amyotrophic Lateral Sclerosis (ALS)

Autophagy Failure Comparison -- AD/PD/ALS/FTD/HD

ALS Pipeline

Ion Channel Dysfunction in ALS

ALS Combination Therapy Matrix

ALS Biomarker-to-Mechanism Mapping

ALS RNA Metabolism and Proteostasis Failure

ALS Regional Onset and Spread: Network-Level Staging Model

FTD-ALS Spectrum

C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

SOD1 Superoxide Dismutase 1 ALS Causal Chain

Pathway Diagram

Outgoing (4767)

Incoming (12629)

Targeting Hypotheses (30)

Mentioning Analyses (30)

Cross-disease neurodegeneration mechanism synthesis

Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Mo

Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular De

Oxidative Stress Upstream of TDP-43 Mislocalization in ALS Motor Neurons

CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

Test Preregistration Analysis

Ferroptosis in ALS motor neuron vulnerability

How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability

What are the mechanisms by which microglial senescence contributes to ALS pathol

Which specific factors in conditioned medium from healthy astrocytes rescue moto

Comparative epigenetic signatures: DNA methylation age acceleration and histone

Comparative epigenetic signatures: DNA methylation age acceleration and histone

Is ferroptosis the primary driver of motor neuron death in ALS or an epiphenomen

Microglial subtypes in neurodegeneration — friend vs foe

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron

test debate

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c

What molecular mechanisms enable functional recovery and muscle re-innervation a

What molecular mechanism causes VCP mutations to trigger aberrant HIF-1α activat

How do the seven novel ALS genes function in animal models to cause neurodegener

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

RNA binding protein dysregulation across ALS FTD AD

What determines the temporal transition from protective to pathological stress g

How can subcellular compartmentalization defects be measured as biomarkers in li

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

What are the neuron-specific effects of ALS-causing mutations on autophagy machi

Experiments (0)

Related Papers (18)

Debates (20)

Structured research brief: Stathmin-2 Splice Switching to Prevent Axonal Degener

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

Test question for preregistration

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

What are the relative contributions of cell-autonomous motor neuron mechanisms v

How does the CCL2-CCR2 chemokine axis at the neuromuscular junction drive select

What is the precise causal sequence of molecular events linking TDP-43 nuclear c

Can targeting oxidative stress pathways (NRF2, SOD1, mitochondrial ROS) upstream

Debate: TREM2 Microglial Activation Rescues Amyloid Clearance in AD

Debate: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fu

Related Research

TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE

Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuro

STING Antagonists as ALS Therapeutics: Drug Repurposing

C9ORF72 autophagy-lysosome collapse across ALS and FTD

TREM2-APOE microglial state switching across AD, ALS, and PD

PINK1/Parkin mitophagy failure across PD, AD, and ALS